S.LiY.et al
Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability
regulating supplements and lifestyle interventions such as exercise provide safe and effective ways to support glucose metabolism and potentially reduce reliance on pharmaceuticals
The Payer Perspective: Payers, including insurers and healthcare systems, are becoming increasingly discerning when it comes to covering pharmaceutical treatments, especially for chronic conditions like obesity and diabetes
doi: 10.1016/0006-3223(86)90334-3 205 ReineckeABrowningMKlein BretelerJKappelmannNResslerKJHarmerCJet al
And no studies have examined the effect of compounded semaglutide formulations, which may contain different excipients